Impact BioMedical (IBO) Q1 2026 earnings summary

Executive summary

• Focused on developing and licensing proprietary healthcare and wellness technologies, with ongoing efforts to expand its portfolio through partnerships and direct sales channels.

• Principal technologies include Linebacker (oncology/inflammatory), Laetose (metabolic health), 3F (functional fragrance), and Equivir (antiviral), with several licensed to third parties for commercialization.

• Operations are conducted through multiple subsidiaries, with majority ownership in key entities.

Financial highlights

• Revenue for Q1 2026 was $7,000, unchanged from Q1 2025, reflecting minimal biotech retail sales.

• Net loss increased to $2,284,000 in Q1 2026 from $1,278,000 in Q1 2025, primarily due to $1,440,000 in stock-based compensation.

• Total assets as of March 31, 2026 were $17,086,000, down from $17,405,000 at December 31, 2025.

• Cash and cash equivalents at quarter-end were $20,000, compared to $3,000 at year-end 2025.

• Operating cash outflow was $464,000 for Q1 2026, improved from $682,000 in Q1 2025.

Outlook and guidance

• Management is exploring capital raises and debt financing to address substantial doubt about the company's ability to continue as a going concern.

• Plans include monetizing intellectual property and tightly controlling operating costs.